5th Circuit’s Mifepristone Stay Triggers SCOTUS Emergency InterventionMay 29, 2026Legal NewsA unanimous 5th Circuit panel reinstated in-person mifepristone rules nationwide on May 1, overriding the Trump administration's position before SCOTUS stepped in four days later.
Supreme Court Stays Fifth Circuit Order, Preserves Mifepristone Telehealth AccessMay 29, 2026Legal NewsThe Supreme Court stayed a Fifth Circuit order that had reinstated in-person mifepristone dispensing rules, preserving telehealth access while litigation continues below.
Fifth Circuit Reinstates Mifepristone In-Person Dispensing Requirement NationwideMay 22, 2026Legal NewsThe Fifth Circuit reinstated mifepristone's in-person dispensing requirement nationwide on May 1, accepting Louisiana's Medicaid-cost standing theory before the Supreme Court intervened May 4.
5th Circuit Orders Nationwide In-Person Mifepristone Dispensing, Prompting Emergency SCOTUS ActionMay 18, 2026Legal NewsA 5th Circuit panel reversed a district court stay and ordered nationwide in-person-only mifepristone dispensing, triggering emergency Supreme Court intervention in May 2026.
Fifth Circuit Blocks Telehealth and Mail Access to Mifepristone NationwideMay 17, 2026Legal NewsThe Fifth Circuit reinstated in-person dispensing rules for mifepristone on May 1, blocking telehealth and mail access nationwide and triggering emergency Supreme Court appeals.
Supreme Court Stays 5th Circuit Order Restoring Mifepristone Dispensing RulesMay 17, 2026Legal NewsThe Supreme Court stayed a 5th Circuit order that would have ended mail-order mifepristone access, with Thomas invoking the Comstock Act in a notable dissent.
Supreme Court Stays Fifth Circuit Mifepristone Ruling, Preserving Telehealth AccessMay 16, 2026Legal NewsThe Supreme Court stayed the Fifth Circuit's mifepristone telehealth ban on May 14, preserving mail-order access while two justices raised the Comstock Act as a future threat.
ImmunityBio Securities Fraud Class Action Targets Cancer Drug ClaimsMay 16, 2026Law and PolicyA securities fraud class action filed May 11 targets ImmunityBio and CEO Patrick Soon-Shiong over alleged false claims that cancer drug Anktiva was a vaccine.
5th Circuit Orders FDA to Reinstate Mifepristone In-Person RequirementMay 6, 2026Law and PolicyThe Fifth Circuit ordered the FDA to reinstate in-person mifepristone dispensing on May 1, 2026; the Supreme Court stayed the ruling three days later.
ImmunityBio Faces Securities Fraud Class Action Over Cancer Drug ClaimsMay 4, 2026Law and PolicyA securities fraud class action filed against ImmunityBio targets executive Patrick Soon-Shiong's claim that cancer drug Anktiva is a vaccine, a description the FDA rejected.